Novocure Ltd (NVCR) Cash Flow Statement

The positive OCF/NI ratio of -0.79 in 2026Q2, despite a net loss, underscores the significant non-cash charges (SBC and D&A) that mask underlying cash generation. However, this is not consistent; in 2026Q1, OCF was -$13.5M against a -$71.1M net loss, indicating volatility. The gap between net income and operating cash flow is primarily attributable to stock-based compensation, which is a real economic cost to shareholders but not a cash outflow, suggesting that cash burn is less severe than net losses imply.

The positive FCF in 2026Q2 is a notable inflection, but it is the first positive quarter in the dataset, and the FCF margin of 3.0% is thin. The erratic pattern—ranging from -$46.3M in 2025Q1 to +$14.9M in 2025Q3—suggests that working capital swings and clinical trial timing drive volatility. Investors should monitor whether this positive FCF is sustainable as revenue growth accelerates, or if it is a one-off due to favorable collections.

The declining CapEx/Rev ratio suggests that NVCR's manufacturing and infrastructure investments are scaling efficiently with revenue, consistent with its disposable-heavy model. However, the absolute CapEx has remained relatively stable around $5-11M per quarter, implying that the company is not investing heavily in new capacity, which may be appropriate given the current revenue base. The low capital intensity supports the potential for high incremental margins if revenue continues to grow.

The large swings in working capital, particularly in accounts receivable and inventory, are a primary driver of the erratic operating cash flow. The positive working capital contribution in 2026Q2 may reflect improved collections, but the negative contributions in other quarters suggest that revenue growth is consuming cash as receivables build. This pattern warrants close monitoring, as it could indicate that the company is extending payment terms to drive adoption, which may not be sustainable.

The absence of capital returns is consistent with a company in a growth phase, prioritizing investment in its pipeline over shareholder distributions. However, with a debt/equity ratio of 0.85 and ongoing net losses, the company may need to raise additional capital if cash burn persists. The lack of buybacks also suggests management is not signaling undervaluation, which may be a concern given the stock's recent underperformance.